Bio-Path Holdings, Inc.

NASDAQ (USD): Bio-Path Holdings, Inc. (BPTH)

Last Price

0.677

Today's Change

0.00 (0.00%)

Day's Change

0.00 - 0.00

Trading Volume

0

Profile
BPTH

Exchange:  NASDAQ Capital Market NASDAQ Capital Market

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Mr. Peter H. Nielsen MBA Mr. Peter H. Nielsen MBA

Full Time Employees:  10 10

IPO Date:  2008-03-04 2008-03-04

CIK:  0001133818 0001133818

ISIN:  US09057N3008 US09057N3008

CUSIP:  09057N300 09057N300

Beta:  0.22 0.22

Last Dividend:  0.00 0.00

Dcf Diff:  -1.29 -1.29

Dcf:  1.96 1.96

Description

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

Address

4710 Bellaire Boulevard,
Bellaire, TX 77401, US

832 742 1357

http://www.biopathholdings.com

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment